Navigation Links
Biodel Inc. to Announce First Quarter Fiscal Year 2008 Financial Results on February 14, 2008
Date:2/8/2008

r

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward- looking statements. The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, our ability to secure FDA approval for our product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; our ability to market, commercialize and achieve market acceptance for product candidates developed using our VIAdel(TM) technology; the progress or success of our research, development and clinical programs, the initiation and completion of our clinical trials, the timing of the interim analyses and the timing or success of our product candidates, particularly VIAject(TM) and VIAtab(TM); our ability to secure additional patents for VIAject(TM) and our other product candidates; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; our estimates of future performance; our ability to enter into collaboration arrangements for the commercialization of our product candidates and the success or failure of those collaborations after consummation, if consummated; the rate
'/>"/>

SOURCE Biodel Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Biodel Inc. Announces Pricing of Public Offering
2. Biodel to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on December 11, 2007
3. Brian J.G. Pereira, M.D. Joins Biodels Board of Directors
4. Biodel Inc. to Present at Natixis Bleichroeder Hidden Gems Conference on October 8, 2007
5. Biodel Inc. to Present at BIO InvestorForum 2007 Conference on October 11, 2007
6. Biodel to Amend June 30, 2007 10-Q to Correct Non-Cash Share-Based Compensation Expense
7. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
8. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
9. Kosan Announces February 28, 2008 Conference Call and Webcast
10. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
11. Volcano Announces FDA 510(k) Clearance of Revolution Rotational Catheter and FFR for the s5i Integrated IVUS Console
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , Not for release, publication or distribution (in whole ... to do so would constitute a violation of the relevant ... the "Company") (LSE: SHP, NASDAQ: SHPG ) notes ... a meeting with representatives of AbbVie. This statement ... approval of AbbVie. A further update will be ...
(Date:7/11/2014)... 11, 2014  Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
(Date:7/10/2014)... Understanding the need for better quality ... the gap that currently exists in this area, ChanTest ... portfolio of validated ion channel and GPCR cell lines. ... as ion channels control many critical physiological functions throughout ... the potential to treat a variety of human diseases. ...
(Date:7/10/2014)... July 10, 2014 EvoDerma ’s NOOME ... This rejuvenating device now comes with a second treatment cup ... time. , The new cup is thinner on the edges ... to target rough, thin and uneven surfaces on the face, ... for a stimulating treatment on areas such as the cheeks ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... BEIJING , June 1 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems ... and,sale of medical products in China , said today that it ... anesthesia product manufactured,by Penlon, a UK firm specializing in anesthesia and breathing ... , ...
... -- Pioneer Surgical Technology, Inc. is pleased to announce that the ... study patients was presented at the recent 10th annual meeting of The ... Orleans by Domagoj Coric , M.D., Chief, Department of Neurosurgery, ... , ...
... June 1 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... has received approval from the Belgian Federal Agency for ... 3 trial examining REOLYSIN in combination with paclitaxel and ... This is the same trial that was agreed to ...
Cached Biology Technology:Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China 2Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China 3Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China 4Two-Year Follow up Data of NuBac® IDE Feasibility Study Was Presented at SAS Meeting 2Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 2Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 3Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 4
(Date:7/11/2014)... Evidence exists that cannabinoid receptor type 1 ... Ca2+ influx, and reduce neurotransmitter release. However, ... 1 can increase extracellular Ca2+ influx and ... his team, Tongji Hospital Affiliated to Tongji ... Technology, China used whole cell voltage-clamp and ...
(Date:7/11/2014)... Janeiro, Brazil- In the brains of all vertebrates, ... allows an electric or chemical signal to be ... synapses, which are the most abundant type of ... formation is crucial for learning, memory, perception and ... synapses critical for brain function. For instance, ...
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... This news release is available in ... November 26, 2013 In the developing world, Cryptosporidium ... decade ago, it announced its presence in the United States, ... the county,s history. Its rapid ability to spread, combined with ...
... new study reveals how pollution causes thunderstorms to leave ... Proceedings of the National Academy of Sciences ... reveal how pollution plays into climate warming. The work ... weather and climate models. Researchers had thought that ...
... mild cognitive impairment is a transitional stage between ... networks during this transformation have yet to be ... University of Technology, China constructed brain networks using ... four populations (normal controls, patients with early mild ...
Cached Biology News:Treatment target identified for a public health risk parasite 2The lingering clouds 2The lingering clouds 3
... GenePix Pro is the industry standard ... unique combination of imaging and analysis tools, ... use. GenePix Pro is included with every ... images from third-party scanners and all types ...
... the one mouse-click image analysis software ... It is the solution for high ... images. MicroVigene is empowered with VigeneTechs ... grid, regional 2D-curve fitting background correction ...
... For applications not requiring confocal, the ... alternative to the Pathway 435. And, the ... if later applications require it. ... can elect to use the laser autofocus, ...
... Proteomic Imaging System, Professional Package Superior ... Dynamic Range: The ProXPRESS 2D Proteomic Imaging ... system for both proteomic and general life ... flexibility, enabling the use of all dyes ...
Biology Products: